drugset / Trial / NCT00152282
A Study to Evaluate the Safety and Effectiveness of Asoprisnil and Estrogen Administration to Postmenopausal Women
RandomizedParallel-groupTriple-blindTreatment
Summary
The objective of this study is to determine the safety and effectiveness of 3 asoprisnil doses when administered to postmenopausal women with Premarin® 0.625 mg.
Timeline
- Start
- 2000-09
- Primary completion
- 2001-08
- Completion
- 2001-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Asoprisnil | Other / unclassified | 5 mg | Oral |
| Subject | Asoprisnil | Other / unclassified | 10 mg | Oral |
| Subject | Asoprisnil | Other / unclassified | 25 mg | Oral |
| Comparator | conjugated estrogens | Other / unclassified | 0.625 mg | Oral |